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Objectives This study ascertains the relationship between continuation or withdrawal of beta-blocker therapy and clinical
outcomes in patients hospitalized with systolic heart failure (HF).
Background Whether beta-blocker therapy should be continued or withdrawn during hospitalization for decompensated HF
has not been well studied in a broad cohort of patients.
Methods The OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Fail-
ure) program enrolled 5,791 patients admitted with HF in a registry with pre-specified 60- to 90-day follow-up at
91 academic and community hospitals throughout the U.S. Outcomes data were prospectively collected and
analyzed according to whether beta-blocker therapy was continued, withdrawn, or not started.
Results Among 2,373 patients eligible for beta-blockers at discharge, there were 1,350 (56.9%) who were receiving
beta-blockers before admission and continued on therapy, 632 (26.6%) newly started, 79 (3.3%) in which ther-
apy was withdrawn, and 303 (12.8%) eligible but not treated. Continuation of beta-blockers was associated with
a significantly lower risk and propensity adjusted post-discharge death (hazard ratio [HR]: 0.60; 95% confidence
interval [CI]: 0.37 to 0.99, p  0.044) and death/rehospitalization (odds ratio: 0.69; 95% CI: 0.52 to 0.92, p 
0.012) compared with no beta-blocker. In contrast, withdrawal of beta-blocker was associated with a substan-
tially higher adjusted risk for mortality compared with those continued on beta-blockers (HR: 2.3; 95% CI: 1.2 to
4.6, p  0.013), but with similar risk as HF patients eligible but not treated with beta-blockers.
Conclusions The continuation of beta-blocker therapy in patients hospitalized with decompensated HF is associated with
lower post-discharge mortality risk and improved treatment rates. In contrast, withdrawal of beta-blocker ther-
apy is associated with worse risk and propensity-adjusted mortality. (Organized Program To Initiate Lifesaving
Treatment In Hospitalized Patients With Heart Failure [OPTIMIZE-HF]; NCT00344513) (J Am Coll Cardiol 2008;
52:190–9) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.03.0481
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July 15, 2008:190–9 Beta-Blocker Continuation or Withdrawal in HFontrolled, randomized clinical trials (3,4) have demon-
trated that certain beta-blockers (carvedilol, metoprolol
uccinate, and bisoprolol) reduce total mortality by approx-
mately 35% in patients with symptomatic chronic HF and
eft ventricular systolic dysfunction (LVSD). National
uidelines (5,6) recommend the use of one of these specific
vidence-based beta-blockers in all patients with current or
rior symptoms of HF and reduced left ventricular ejection
raction (LVEF), in the absence of contraindications or
ntolerance.
Despite the efficacy of HF medical therapy, patients may
till decompensate and require hospitalization for HF. An
ncreasing proportion of patients presenting to the hospital
ith HF (more than two-thirds in recent studies) have been
eceiving beta-blocker therapy as part of their outpatient
edical regimen (7). Unfortunately, whether beta-blocker
herapy should be continued or withdrawn during HF
ospitalization in such patients has not been well studied.
here have been no clinical trials that have randomized HF
atients treated with beta-blockers before hospital admis-
ion to continuation or withdrawal of beta-blocker therapy.
or have there been any trials that have assessed initiation
f beta-blocker therapy in the first 48 h of hospitalization
or HF. A few recent retrospective analyses (8–11) have
ompared continuation versus withdrawal of beta-blocker
herapy among hospitalized HF patients enrolled in ran-
omized clinical trials that were testing other HF treat-
ents or monitoring strategies. However, as randomized
linical trials enroll only select HF patients and generally
rovide much closer monitoring and follow-up compared
ith the usual care setting, the generalizability of the
ndings from these studies may be limited. Furthermore,
hese studies were not able to document new contraindica-
ions or intolerance of beta-blocker therapy during the
eriod of follow-up or able to compare outcomes to HF
atients who were otherwise eligible but not treated with
eta-blockers.
The OPTIMIZE-HF (Organized Program to Initiate
ifesaving Treatment in Hospitalized Patients with Heart
ailure) is a large, national hospital-based registry and
rocess-of-care improvement initiative for patients hospi-
alized with HF (12). The present study examines data from
PTIMIZE-HF to explore the relationship of continua-
ion or withdrawal of beta-blocker therapy to post-discharge
linical outcomes in a general population of patients hospi-
alized with systolic HF.
ethods
tudy design. The OPTIMIZE-HF program is a hospital-
ased registry and process-of-case improvement program de-
igned to evaluate and enhance the quality of care for patients
ospitalized with HF. The OPTIMIZE-HF program has
een described in detail elsewhere (12–15) and will be briefly
ummarized. From March 1, 2003, to December 31, 2004,
ligible adult patients hospitalized with HF at participating oospitals were enrolled. All regions
f the U.S. were represented, and
ll types of institutions, from
ommunity hospitals to large ter-
iary medical centers, were in-
luded. A list of participating
ospitals has been published
14). Hospital teams used HF
ase-ascertainment methods
imilar to those of the Joint
ommission (16). Patients qual-
fied for enrollment if they were
ospitalized for episodes of new or worsening HF as the
rimary cause of admission or if significant HF symptoms
eveloped during hospitalization for another primary diag-
osis, with HF being the primary discharge diagnosis
12–15). Consecutive patients were enrolled irrespective of
heir ventricular function, including systolic dysfunction
ocumented by a left ventricular ejection fraction (LVEF)
40%, HF symptoms in the setting of preserved left
entricular systolic function (diastolic dysfunction HF), or
F without left ventricular function measurement (12–15).
Using a web-based information system, data were cap-
ured regarding various patient characteristics at admission
nd discharge, including laboratories, procedures, LVEF,
rug contraindications or intolerance, and prescribed med-
cations (12). Automated electronic data checks were used
o prevent out-of-range entry or duplicate patients. A
atabase audit was performed, based on predetermined
riteria, of a random sample of 5% of the first 10,000
atients verified against source documents (13). A pre-
pecified subgroup (10%) from 91 participating hospitals
ad 60- to 90-day follow-up data collected. The protocol
as approved by each participating center’s institutional
eview board or through the use of a central institutional
eview board. Written informed consent was obtained
efore enrollment from patients who participated in the
ollow-up data collection. The registry coordinating center
as Outcome Sciences, Inc. (Cambridge, Massachusetts).
The present study was pre-specified in the study protocol
nd aimed to compare outcomes in the first 60 to 90 days
fter HF hospital discharge among patients eligible for
eta-blocker therapy who were receiving beta-blockers be-
ore hospitalization and continued on therapy through
ischarge, patients who were eligible for beta-blocker ther-
py for whom beta-blocker therapy was withdrawn during
ospitalization, and patients eligible for beta-blocker ther-
py who were not treated with beta-blocker therapy before
ospitalization or at the time of hospital discharge. The
urrent analysis was confined to those patients who had
ocumented LVEF 40% or moderate-to-severe systolic
ysfunction by qualitative assessment. We excluded patients
ith documented contraindications or intolerance to beta-
lockers at the time of hospital discharge. Contraindications
ncluded allergy, second- or third-degree heart block with-
Abbreviations
and Acronyms
CI  confidence interval
HF  heart failure
HR  hazard ratio
LVEF  left ventricular
ejection fraction
LVSD  left ventricular
systolic dysfunction
OR  odds ratiout a pacemaker, symptomatic bradycardia, symptomatic
h
(
b
p
S
b
l
s
d
c
b
t
K
s
e
m
d
r
i
p
c
w
h
s
a
a
c
t
t
u
s
w
b
E
p
m
c
a
O
t
c
(
C
R
T
p
a
p
9
t
c
p
t
w
t
p
e
L
H
r
p
6
5
t
a
5
w
d
e
o
a
n
2
d
b
b
w
t
A
b
o
(
7
g
w
P
s
t
c
L
B
A
p
a
w
d
u
s
p
C
p
w
v
a
n
t
(
t
192 Fonarow et al. JACC Vol. 52, No. 3, 2008
Beta-Blocker Continuation or Withdrawal in HF July 15, 2008:190–9ypotension, cardiogenic shock, or reactive airway disease
14,15). The study also assessed whether continuation of
eta-blocker therapy was well tolerated, as gauged by
ersistence of treatment during 60- to 90-day follow-up.
tatistical analysis. All statistical analyses were performed
y Duke Clinical Research Institute (Durham, North Caro-
ina). Eligibility for beta-blocker therapy used specifications
imilar to the Joint Commission and excluded patients with
ocumented contraindications, intolerance, or other physi-
ian documentation. Patient characteristics and evidence-
ased treatments at hospital discharge were compared using
he Pearson chi-square test for categorical variables and the
ruskal-Wallis test for continuous variables. The relation-
hip between beta-blocker therapy group and outcomes was
valuated with propensity score and multivariable adjust-
ent. Models of mortality from hospital discharge to 90
ays and the combination of post-discharge mortality or
ehospitalization have been developed to determine signif-
cant factors to use when applying adjusted models, as
reviously described (13–15). Baseline demographic, clini-
al, and treatment factors as well as hospital course factors
ere applied to logistic regression and Cox proportional
azards models using both stepwise and backward variable
election techniques. The assumption of proportional haz-
rds was checked in Cox models for key variables (17). The
ssumption of linearity was checked in each model for the
ontinuous variables by using restricted cubic splines. When
he relationship was found to be nonlinear, appropriate
ransformations were applied. Propensity score analysis was
sed to account for potential medication selection bias. The
et of all possible covariates that were related to selection
as applied to a logistic regression model, with the proba-
ility of receiving the medication generated as the score.
ach model included 2 treatment indicators plus the pro-
ensity score and covariate adjustment. Generalized esti-
ating equations were also performed to account for the
orrelation of the data within the same hospital in the
djusted models. A previously derived and validated
PTIMIZE-HF post-discharge mortality risk prediction
ool was used to estimate mortality based on admission
haracteristics for the beta-blocker treatment patient groups
18). SAS version 8.2 (SAS Institute Inc., Cary, North
arolina) was used for all statistical analyses.
esults
he OPTIMIZE-HF program enrolled a total of 48,612
atients hospitalized for HF at 259 U.S. hospitals. This
nalysis was confined to those patients from 91 hospitals
articipating in the hospital registry and pre-specified 60- to
0-day post-discharge follow-up. Of the 5,791 patients in
he pre-specified cohort with 60- to 90-day follow-up data
ollection, left ventricular function was assessed in 5,117
atients, and 2,720 patients had documented LVSD. Pa-
ient demographics for the hospital and follow-up cohort
ith LVSD are shown in Table 1. The mean patient age in 0he follow-up group was 69.5  14.5 years; 63% of the
atients were men, and 75% were Caucasian. The HF
tiology was ischemic in 52% of the patients; the mean
VEF was 24.3  7.8%, and 89.3% of patients had known
F before admission. At hospital admission, pulmonary
ales were present in 62% of patients, an S3 gallop was
resent in 18%, and lower extremity edema was found in
3%. Medications on admission included a beta-blocker in
7% of patients, an angiotensin-converting enzyme inhibi-
or in 47%, an angiotensin receptor blocker in 12%, an
ldosterone antagonist in 10%, and digoxin in 30%.
Patients were hospitalized for a mean of 6.4 days (median
.0 days). Of the 2,720 patients with LVSD, 2,373 (87.2%)
ere eligible for beta-blocker therapy at the time of hospital
ischarge, with no documented contraindications or intol-
rance. There were 347 patients (12.8%) ineligible because
f contraindications or intolerance to beta-blocker therapy
t hospital discharge (n  299) or discharge to skilled
ursing care facility, transfer, or hospice (n  48). Of the
,373 patients eligible for beta-blocker therapy at hospital
ischarge, 1,350 patients (56.9%) were continued on beta-
locker therapy, 79 (3.3%) were withdrawn from beta-
locker therapy, and 303 (12.8%) were not treated. There
ere 632 patients (26.6%) newly started on beta-blocker
herapy and 9 patients with missing treatment data (0.4%).
mong the 1,537 patients receiving beta-blocker therapy
efore hospital presentation, 1,350 (87.8%) were continued
n beta-blocker therapy and 187 (12.2%) were withdrawn
108 with documented contraindications or intolerance and
9 without). Patient characteristics for the 4 treatment
roups included in this study (continued, newly started,
ithdrawn, eligible but not treated) are shown in Table 2.
atients in the group continued on beta-blockers were of
imilar age to those withdrawn but younger than those not
reated. Vital signs and lab values were similar in those
ontinued and withdrawn from beta-blocker therapy. The
VEF was lower in patients withdrawn from beta-blockers.
eta-blocker use and clinical outcomes. UNADJUSTED
NALYSES. In the overall cohort of beta-blocker–eligible
atients with HF and LVSD, mortality at 60 to 90 days
fter hospital discharge was 8.7% (Table 3). Readmission
ithin the 60- to 90-day follow-up period was 30.2%, and
eath/rehospitalization occurred in 34.8%. Patients contin-
ed on beta-blocker therapy from the time of admission had
horter hospital length of stay compared with eligible
atients who were not treated with beta-blockers (Table 3).
ontinued patients were found to have significantly lower
ost-discharge mortality rates during follow-up compared
ith those eligible but not treated with beta-blockers (8.7%
s. 13.8%, p  0.046) (Table 3). The Kaplan-Meier
ctuarial mortality curves for eligible patients continued,
ewly started, withdrawn, and not treated with beta-blocker
herapy are shown in Figure 1. The unadjusted hazard ratios
HRs) for post-discharge mortality with beta-blocker con-
inuation compared to nonuse among eligible patients was
.60 (95% confidence interval [CI]: 0.38 to 0.94, p 
0
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July 15, 2008:190–9 Beta-Blocker Continuation or Withdrawal in HF.027). Furthermore, there was no evidence that continua-
ion of beta-blocker therapy was associated with increased
isk of early rehospitalization (32.2% vs. 35.6%; HR: 0.86;
5% CI: 0.66 to 1.12, p  0.25). Continuation of beta-
locker therapy was associated with a significantly lower risk
f the combined mortality and/or rehospitalization end
oint (36.1% vs. 43.2%; odds ratio [OR]: 0.70; 95% CI:
.54 to 0.91, p 0.007). In unadjusted analyses, withdrawal
f beta-blocker therapy was associated with substantially
ncreased risk of post-discharge death compared with con-
inuation of beta-blocker therapy (24.4% vs. 8.7%, HR:
Patient Demographics at HospitalAdmission and Follow-Up C hor With LVSD
Table 1 Patient Demographics at HospitalAdmission and Follow-Up Cohort Wi
Characteristic
O
Mean age, yrs (SD)
Female gender, n (%)
Race, n (%)
Caucasian
African American
Native American
Unknown
Other
Hispanic ethnicity, n (%)
HF etiology, n (%)
Ischemic
Nonischemic
Medical history, n (%)
Hypertension
CAD
Hyperlipidemia
Atrial arrhythmia
Pulmonary/COPD
Non–insulin-treated diabetes
Insulin-treated diabetes
Cigarette smoker
Renal insufficiency (SCr 2.0)
Anemia
Peripheral vascular disease
Thyroid abnormality
CVA/TIA (prior)
LVEF (%), mean (SD)
Weight admission (kg), mean (SD)
Heart rate admission (beats/min), mean (SD)
SBP admission (mm Hg), mean (SD)
DBP admission (mm Hg), mean (SD)
Rales, n (%)
Lower extremity edema, n (%)
JVD, n (%)
Serum creatinine admission (mg/dl), mean (SD)
Serum Na admission (mEq/l), mean (SD)
Hemoglobin admission (g/dl), mean (SD)
BNP admission (pg/ml), median (25th, 75th)
Troponin I admission (ng/ml), median (25th, 75th)
BNP B-type natriuretic peptide; BP blood pressure; CAD corona
cerebral vascular accident/transient ischemic attack; DBP  diastolic
left ventricular ejection fraction; LVSD  left ventricular systolic dysfu.82; 95% CI: 1.46 to 5.48, p  0.002), but the death/ pehospitalization rates were similar (Fig. 1, Table 3). When
atients withdrawn from beta-blocker therapy were com-
ared with patients eligible but not treated, mortality risk
ended to be higher (HR: 1.69; 95% CI: 0.81 to 3.52, p 
.16) (Table 3). Patients ineligible for beta-blocker therapy
wing to contraindications or intolerance were also at high
isk for adverse outcomes, with post-discharge mortality
3.1%, rehospitalization 30.8%, and death/rehospitalization
3.4%.
DJUSTED ANALYSES. The influence of beta-blocker treat-
ent on follow-up outcomes was tested in risk- and
SD
Registry With LVSD
(n  20,118)
Follow-Up Cohort With LVSD
(n  2,720)
0.3 (14.5) 69.5 (14.5)
797 (39) 1,006 (37)
266 (71) 2,037 (75)
212 (21) 560 (21)
73 (1) 11 (1)
541 (3) 27 (1)
764 (4) 66 (2)
789 (4) 80 (3)
933 (54) 1,401 (52)
185 (46) 1,319 (48)
274 (66) 1,832 (67)
869 (54) 1,460 (54)
913 (34) 1,121 (41)
742 (29) 852 (31)
057 (25) 740 (27)
912 (24) 678 (25)
110 (15) 447 (16)
997 (20) 582 (21)
798 (19) 518 (19)
811 (14) 510 (19)
754 (14) 401 (15)
621 (13) 400 (15)
847 (14) 387 (14)
4.3 (7.7) 24.3 (7.8)
2.0 (24.4) 83.2 (24.2)
9.1 (21.7) 88.0 (21.4)
5.2 (30.9) 133.2 (30.1)
7.4 (20.0) 75.6 (19.5)
502 (63) 1,661 (62)
132 (62) 1,680 (63)
598 (33) 847 (31)
1.7 (1.6) 1.6 (1.1)
6.5 (11.4) 136.9 (8.7)
2.6 (3.2) 12.5 (2.4)
160 (597, 2,270) 1,130 (573, 2,360)
.13 (0.06, 0.30) 0.19 (0.07, 0.40)
disease; COPD chronic obstructive pulmonary disease; CVA/TIA
ressure; HF  heart failure; JVD  jugular venous distention; LVEF 
SBP  systolic blood pressure; SCr  serum creatinine.th LV
verall
7
7,
14,
4,
10,
9,
13,
10,
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5,
5,
4,
3,
3,
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2,
2,
2,
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Beta-Blocker Continuation or Withdrawal in HF July 15, 2008:190–9ariables predictive of post-discharge mortality as well as
ropensity for beta-blocker use and correlation of data
ithin the same hospital, continuation of beta-blocker
herapy, when compared with no beta-blocker use among
ligible patients, was still associated with a reduced risk
f all-cause mortality in the first 60 to 90 days after
ospital discharge (HR: 0.60; 95% CI: 0.37 to 0.99, p 
atient Characteristics of Follow-Up Cohort With LVSD by Beta-Blo
Table 2 Patient Characteristics of Follow-Up Cohort With LVSD
Eligible, Beta-Blocker
Therapy Continued
(n  1,350)
Mean age, yrs (SD) 69.3 (13.4)
Female gender, n (%) 486 (36)
Race, n (%)
Caucasian 1,027 (76)
African American 273 (20)
Hispanic ethnicity, n (%) 34 (3)
HF etiology, n (%)
Ischemic 793 (59)
Nonischemic 557 (41)
Medical history, n (%)
Insulin-treated diabetes 265 (20)
Non–insulin-treated diabetes 365 (27)
Hypertension 963 (71)
CAD 831 (62)
Hyperlipidemia 652 (48)
Atrial arrhythmia 438 (32)
Pulmonary/COPD 354 (26)
Cigarette smoker 263 (20)
Renal insufficiency 283 (21)
Anemia 265 (20)
Peripheral vascular disease 226 (17)
Thyroid abnormality 190 (14)
CVA/TIA (prior) 204 (15)
LVEF (%), mean (SD) 24.4 (7.7)
SBP admission (mm Hg), mean (SD) 132.7 (29.3)
DBP admission (mm Hg), mean (SD) 75.0 (18.3)
Heart rate admission (beats/min), mean (SD) 84.4 (20.2)
Rales admission, n (%) 816 (62)
Lower extremity edema admission, n (%) 828 (63)
JVD admission, n (%) 433 (37)
Serum Na admission (mEq/l), mean (SD) 137.7 (4.5)
Serum creatinine admission (mg/dl), mean (SD) 1.6 (1.2)
Hemoglobin admission (g/dl), mean (SD) 12.6 (2.1)
BNP admission (pg/ml), median (25th, 75th) 1,120 (577, 2,270)
Troponin I admission (ng/ml), median (25th, 75th) 0.2 (0.1, 0.4)
SBP discharge (mm Hg), mean (SD) 118.7 (21.0)
DBP discharge (mm Hg), mean (SD) 65.7 (12.2)
Heart rate discharge (beats/min) mean (SD) 74.4 (13.1)
Rales discharge, n (%) 169 (14)
Lower extremity edema discharge, n (%) 300 (26)
JVD discharge, n (%) 65 (5)
Post-discharge mortality risk point score (SD)† 42.5 (7.8)
Expected post-discharge mortality risk (%), mean (SD)† 5.7 (4.7)
Pearson chi-square test for categorical variables and the Kruskal-Wallis test for continuous variab
dmission characteristics entered into a previously derived and validated model.
Abbreviations as in Table 1..044) (Table 4). Continuation of beta-blocker therapy was blso associated with lower post-discharge mortality/
ehospitalization. Newly started beta-blocker therapy was
lso associated with improved outcomes compared to no
eta-blocker use among eligible patients (Table 4). In
ontrast, after risk and propensity adjustment, withdrawal of
eta-blocker therapy was associated with a substantially
igher risk of death compared with continuation of beta-
Treatment Group
eta-Blocker Treatment Group
le, Beta-Blocker
herapy Newly
Started
(n  632)
Eligible, Beta-Blocker
Therapy Withdrawn
(n  79)
Eligible, Beta-Blocker
Therapy Not
Prescribed
(n  303) p Value*
.0 (15.3) 69.3 (13.1) 72.4 (13.0) 0.001
30 (36) 24 (30) 125 (41) 0.224
38 (71) 54 (70) 227 (75) 0.025
57 (25) 22 (29) 58 (19) 0.034
18 (3) 2 (3) 13 (4) 0.416
27 (36) 39 (49) 157 (52) 0.001
05 (64) 40 (51) 146 (48) 0.001
75 (12) 20 (25) 35 (12) 0.001
43 (23) 21 (27) 82 (27) 0.197
04 (64) 51 (65) 198 (65) 0.004
33 (67) 42 (53) 153 (51) 0.001
01 (32) 23 (29) 103 (34) 0.001
50 (24) 17 (22) 111 (37) 0.001
44 (23) 16 (20) 86 (28) 0.152
68 (27) 12 (16) 68 (23) 0.003
73 (12) 18 (23) 49 (16) 0.001
00 (16) 8 (10) 54 (18) 0.051
64 (10) 12 (15) 42 (14) 0.002
77 (12) 16 (20) 51 (17) 0.100
58 (9) 12 (15) 52 (17) 0.001
.1 (7.8) 21.7 (7.9) 25.5 (7.5) 0.001
.5 (30.6) 133.0 (27.4) 132.9 (26.5) 0.001
.8 (20.1) 75.2 (16.4) 75.4 (16.7) 0.001
.9 (22.6) 83.7 (19.7) 90.6 (19.8) 0.001
82 (62) 48 (62) 181 (61) 0.986
95 (64) 51 (67) 172 (59) 0.464
95 (36) 16 (24) 81 (31) 0.097
.0 (4.0) 136.4 (4.6) 137.7 (4.6) 0.056
.4 (1.0) 1.7 (0.9) 1.5 (0.9) 0.001
.8 (2.1) 12.7 (1.7) 12.5 (2.1) 0.014
20 (587, 2,140) 1,224 (663, 2,815) 1,150 (668, 2,360) 0.664
.3 (0.1, 0.5) 0.2 (0.1, 0.3) 0.2 (0.1, 0.4) 0.001
.8 (20.6) 121.0 (21.3) 119.2 (18.9) 0.519
.0 (13.4) 68.9 (14.2) 66.4 (11.3) 0.001
.3 (14.4) 78.0 (14.6) 79.7 (14.6) 0.001
59 (10) 5 (7) 37 (14) 0.074
20 (22) 21 (31) 69 (27) 0.112
29 (5) 3 (4) 8 (3) 0.403
.4 (8.6) 43.3 (9.0) 42.9 (7.6) 0.001
.6 (4.3) 6.7 (6.9) 5.8 (4.5) 0.001
PTIMIZE-HF 60 and 90 days post-discharge mortality risk score and projected mortality based oncker
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ost-discharge risk to those eligible but not treated with
eta-blockers (Table 4).
OLERABILITY. During the 60- to 90-day post-discharge
ollow-up period, continuation of beta-blocker therapy was
ery well tolerated, as evidenced by 93.6% of patients
emaining on beta-blocker therapy after discharge. Newly
tarting beta-blocker therapy was also well tolerated, with
1.9% of patients remaining on therapy. Of the cohort of
ligible patients who were not prescribed beta-blocker
herapy either before admission or at time of hospital
ischarge, only 23.9% were started on beta-blocker therapy
fter discharge within the 60- to 90-day follow-up period
continued cohort 93.6% vs. not-treated cohort 23.9%, OR:
6.7, 95% CI: 32.1 to 68.0, p  0.0001). Eligible patients
n whom beta-blocker therapy was withdrawn during hos-
italization were also less likely to be receiving treatment
uring 60- to 90-day post-discharge follow-up, with only
6.5% restarted on therapy (continued cohort 93.6% vs.
ithdrawn cohort 56.5%; OR: 11.3, 95% CI: 6.5 to 19.7,
 0.0001). For patients continued on beta-blockers, 88.2%
linical Outcomes of Follow-Up Cohortth LVSD by B ta-Blocker Treatmen Group: Unadjusted
Table 3 Clinical Outcomes of Follow-Up CohortWith LVSD by Beta-Blocker Treatment Group: Unadjust
Eligible, Follow-Up
Cohort With LVSD
(n  2,373)
Eligible, Beta-Blocker
Therapy Continued
(n  1,350)
Median length of stay, days
(IQR)
5.0 (3, 8) 4.0 (3, 7)
Mean length of stay, days (SD) 6.4 (7.0) 6.1 (6.7)
60- to 90-day post-discharge
mortality, %
8.7 8.7
60- to 90-day readmission, % 30.2 32.2
60- to 90-day mortality and/or
rehospitalization, %
34.8 36.1
Kruskal-Wallis test; †log-rank test; ‡Pearson chi-square test.
IQR  interquartile range; LVSD  left ventricular systolic dysfunction.
25
Withdrawn Not Treated Continued
%
)
NewlyStarted
15
20
lit
yR
at
e
(%
5
10
M
or
ta
0
0 15 30 45 60 75
Days Since Discharge
Patients at risk:
Withdrawn
Not Treated
79 77 73 68 2666
303 275 269 262 242 114
Continued 1303 1268 1236 1123 536
NewlyStarted 632 609 591 575 531 274
10
51
224
110
1350
Figure 1 Post-Discharge Survival by
Beta-Blocker Treatment Groups
Kaplan-Meier survival curves by
beta-blocker treatment groups. Log-rank test: p  0.001.oere maintained on at least their admission dose of medication
72.9% same dose and 15.3% increased) during the hospital-
zation and 11.8% had their dosage reduced. During the first
0 to 90 days of post-discharge follow-up, the discharge dose
f beta-blockers was reduced in only 11.7% of patients,
aintained in 73.4%, and increased in 15%.
ubgroups. In the risk- and propensity-adjusted model for
ortality and the combined model for mortality and/or
ehospitalization, the association of continuation of beta-
locker therapy with improved outcomes was consistent in
ll clinically relevant subgroups examined, including age,
ender, race, diabetes status, chronic obstructive pulmonary
isease status, and renal function. The risk-adjusted mor-
ality and mortality/rehospitalization rates were similar for
atients in whom the beta-blocker dosage was reduced
uring hospitalization compared with those in whom beta-
locker dosage was maintained or increased (death/
ehospitalization 36.6% vs. 37.2%, OR: 0.91, 95% CI: 0.61
o 1.36, p  0.64).
iscussion
he OPTIMIZE-HF program provides an important op-
ortunity to evaluate the influence of continuation and
ithdrawal of beta-blocker therapy during hospitalization
or HF. This registry contains substantially more detailed
nformation on patient characteristics, presenting symp-
oms, treatments, and outcomes than has previously been
vailable in administrative datasets or other registries (12).
n this detailed analysis, the vast majority of hospitalized
F patients who were treated with beta-blockers before
dmission were able to be continued on beta-blocker ther-
py during the hospitalization. Continuation of beta-
locker therapy was associated with substantially lower risk
nd propensity adjusted post-discharge mortality risk.
ithdrawal of beta-blockers was associated with excess
djusted mortality risk. In addition, continuation of beta-
locker therapy was well tolerated after discharge, and
ubstantially more patients were treated as outpatients with
his strategy. These findings extend the results of prior
le, Beta-Blocker
erapy Newly
Started
(n  632)
Eligible, Beta-Blocker
Therapy Withdrawn
(n  79)
Eligible, Beta-Blocker
Therapy Not
Prescribed
(n  303) p Value
5.0 (3, 8) 6.0 (3, 9) 5.0 (3, 8) 0.001*
6.7 (6.2) 7.1 (5.4) 7.2 (10.0) 0.001*
4.5 24.4 13.8 0.001†
24.1 24.1 35.6 0.001‡
27.5 37.7 43.2 0.001‡ed
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Beta-Blocker Continuation or Withdrawal in HF July 15, 2008:190–9zed clinical trials to a diverse cohort of patients hospitalized
ith HF in the usual care setting from all regions of the
ountry and have significant clinical implications.
Neurohormonal inhibition is the foundation of modern
ystolic HF management. A meta-analysis of 22 placebo-
ontrolled randomized beta-blocker trials involving 10,132
hronic systolic HF patients demonstrated an OR for total
ortality of 0.65 (95% CI: 0.53 to 0.80) in favor of
eta-blocker use (19). Accordingly, national practice guide-
ines (5,6) recommend use of beta-blockers in all stable
utpatients with systolic HF in the absence of contraindi-
ations on the basis of their proven ability to significantly
educe mortality in these patients. In contrast to the
ompelling evidence for beta-blocker use in the chronic
table setting, whether beta-blocker therapy should be
ontinued during hospitalization among decompensated
F patients is a commonly encountered and important
linical issue for which little data exist.
There have been no randomized clinical trials and rela-
ively little observational data on the impact of continuing or
ithdrawing beta-blocker therapy after hospitalization for
orsening HF. A retrospective analysis of patients enrolled
n the OPTIME-CHF (Outcomes of the Prospective Trial
f Intravenous Milrinone for Exacerbations of Chronic
eart Failure) study (8) reported worse outcomes for the 47
atients in whom beta-blocker were withdrawn of the 212
atients treated with beta-blockers at the time of the
dmission for acute decompensated HF. A retrospective
nalysis of patients enrolled in FIRST (Flolan International
Effect of Beta-Blocker Treatment Group on All-CDeath/Rehospitalization at 60 to 90 Days AfterPropensity-Adjusted Analyses
Table 4
Effect of Beta-Blocker Treatment G
Death/Rehospitalization at 60 to 9
Propensity-Adjusted Analyses
n
Mortality
Continued on beta-blocker therapy
versus eligible but not treated
1,350 vs. 303
Newly started on beta-blocker
therapy versus eligible but not
treated
632 vs. 303
Withdrawn from beta-blocker therapy
versus eligible but not treated
79 vs. 303
Withdrawn from beta-blocker
therapy versus continued on beta-
blocker therapy
79 vs. 1,35
Mortality/rehospitalization
Continued on beta-blocker
therapy versus eligible but not
treated
1,350 vs. 303
Newly started on beta-blocker
therapy versus eligible but not
treated
632 vs. 303
Withdrawn from beta-blocker
therapy versus eligible but not
treated
79 vs. 303
Withdrawn from beta-blocker
therapy versus continued on beta-
blocker therapy
79 vs. 1,35andomized Survival Trial) (9) reported no excess risk for ratients treated with beta-blockers at the time of hospital
resentation for HF. A study of patients receiving beta-
lockers at the time of HF hospitalization in the ESCAPE
Evaluation Study of Congestive Heart Failure and Pulmo-
ary Artery Catheterization) trial showed that 268 of 432
atients who remained on beta-blocker therapy had a
horter length of stay and lower 6-month mortality rate
11). Continuation versus withdrawal of beta-blocker ther-
py remained independently associated with lower mortality
n a multivariable analysis (11). In an analysis of COMET
Carvedilol or Metoprolol European Trial), 752 of 3,029
atients had a nonfatal HF hospitalization while receiving
tudy beta-blocker treatment (10). Of these, 529 (70%) of
atients were continued on beta-blocker therapy at the same
ose, 162 (22%) had a dose reduction, and 61 patients (8%)
ad beta-blocker treatment withdrawn. The risk of death
as higher in patients in whom beta-blocker therapy was
iscontinued or for whom the dose was reduced compared
ith those patients who were continued on beta-blocker
herapy (10).
Each of these prior analyses included select patients
nrolled and followed in randomized clinical trials. The
ean age of the patients was approximately 64 years, 75%
ere men, and comorbidities were relatively infrequent
8–11). As these patients were treated in clinical trials with
nvestigators and coordinators with considerable experience
n managing patients with HF, these studies cannot provide
nformation as to whether similar results can be expected in
he general group of patients hospitalized with HF. Our
Mortality andharge: Risk- and
on All-Cause Mortality and
s After Discharge: Risk- and
Hazard Ratio 95% Confidence Interval p Value
0.60 0.37–0.99 0.044
0.41 0.22–0.78 0.006
1.41 0.76–2.61 0.277
2.34 1.20–4.55 0.013
0.69 0.52–0.92 0.012
0.61 0.44–0.83 0.002
0.77 0.44–1.35 0.360
1.11 0.67–1.85 0.689auseDi c
roup
0 Day
0
0esults in real-world patients in the usual care setting
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July 15, 2008:190–9 Beta-Blocker Continuation or Withdrawal in HFnvolving clinicians and hospitals from all regions of the
ountry show that discontinuation of beta-blocker therapy
uring a HF hospitalization is associated with substantially
orse risk-adjusted outcomes compared to continuation.
hese findings were derived from a broad cohort with a
igh proportion of older HF patients with multiple comor-
idities who are more representative of those seen in general
ractice (12,13).
The decision to discontinue beta-blocker therapy in
ertain patients hospitalized with HF may be related to a
reater state of patient decompensation, which may account
or poor outcomes among these patients rather than the
ithdrawal of beta-blocker therapy per se (10). Though
ithdrawal of beta-blockers was associated with a few
ndicators of more severe HF, it remained significantly and
ndependently associated with increased mortality after
djustment for multiple covariates and propensity score. In
he absence of symptomatic bradycardia, symptomatic hy-
otension, or cardiogenic shock, the decision to discontinue
eta-blocker therapy among these patients is based primar-
ly on clinical judgment, likely influenced by individual
linician experience (11). Patients who were continued on
eta-blocker therapy had similar admission vital signs,
hysical exam findings, and laboratories to those in whom
eta-blocker therapy was discontinued. In this study, im-
roved outcomes with continued beta-blocker therapy per-
isted after controlling for factors associated with the deci-
ion to discontinue beta-blocker therapy and those
ssociated with post-discharge outcomes. However, with an
bservational analysis, it is possible that not all factors that
ay have influenced the decision to continue, withdraw, or
ot initiate beta-blocker therapy have been fully captured,
nd these unmeasured factors may influence the findings.
Abrupt cessation of beta-blockers has been reported to be
ssociated with ischemia, hypertension, ventricular arrhyth-
ias, and, in some cases, myocardial infarction (20,21).
ithdrawal of beta-blocker therapy in patients hospitalized
ith HF thus could be associated with outcomes worse than
aving never been treated in the first place. In this study,
F patients in whom beta-blocker therapy was withdrawn
ere at higher risk for mortality and death/rehospitalization
n the first 60 to 90 days compared with those continued,
ut this risk was not significantly different from those
ligible but not treated. However, as there was a trend for
orse outcomes, further study will be necessary to deter-
ine whether withdrawal of beta-blockers is associated with
ncreased risk beyond that of not deriving the benefits on
ngoing beta-blocker treatment in this patient population.
Several recent studies (22–24) have reported that many
F patients who are candidates for beta-blockers do not
eceive them. In addition, the rate of beta-blocker prescrip-
ions at hospital discharge is lowest for patients at the
reatest risk of death, who in fact derive the most benefit
rom their use (24). In an analysis of 103 acute-care
ospitals in Ontario, Canada, comprising 1,418 patients
ith LVEF40%, beta-blockers were prescribed to 40% of whe lowest-risk patients but to only 23% with the highest
isk of death on the basis of a previously derived and
alidated 1-year mortality risk prediction model (24). Med-
cation prescription at the time of discharge has been shown
o be the strongest predictor of long-term adherence to drug
herapy (25,26). Discontinuation of evidence-based HF
edications during hospital admission, when not absolutely
ecessary, thus can have deleterious effects on treatment
ates and long-term clinical outcomes. As shown in this
tudy, when beta-blocker therapy was disrupted during
ospitalization, a substantial proportion of patients did not
ave this therapy re-initiated after discharge. In a prospec-
ive longitudinal follow-up study in a cohort of consecutive
atients with chronic HF seen at a specialized HF outpa-
ient clinic (23), the most common reason for systolic HF
atients not to be treated with beta-blocker therapy was
iscontinuation during hospitalization and failure to restart
reatment despite the absence of contraindications. Contin-
ation of beta-blocker therapy during HF hospitalization,
henever possible, represents an important strategy to
mprove overall treatment rates with this guideline-
ecommended therapy.
tudy limitations. The reason(s) for beta-blocker continua-
ion and withdrawal during hospitalization were not collected;
herefore, we cannot determine the specific rationale for these
reatment decisions. Contraindications and intolerance were as
ocumented in the medical record. A proportion of patients
eported to be eligible for beta-blocker therapy but not treated
ay have had contraindications or intolerance (before hospi-
alization or in-hospital) that were present but not docu-
ented. Medication use in this study was as reported by
atients and as documented in the medical record; actual
dherence rates may have been lower. Follow-up data were
imited to the first 60 to 90 days after discharge, and only a
ubset of hospitals and patients participated in the collection of
ollow-up data. OPTIMIZE-HF was not a randomized clin-
cal trial, and, therefore, interpretation of results is subject to
imitations. Despite covariate adjustment and propensity
atching, other measured and unmeasured factors may have
nfluenced improvements in clinical outcomes associated with
ontinuation of beta-blocker therapy. These findings may not
pply to hospitals that differ in patient characteristics or care
atterns from OPTIMIZE-HF hospitals, although a recent
tudy (27) suggests that patients enrolled in OPTIMIZE-HF
ave similar demographics to those hospitalized nationally.
onclusions
ata from this study of a large, representative cohort of HF
atients indicate that continuation of beta-blocker therapy
mong patients hospitalized with HF is associated with
etter outcomes than those in whom beta-blocker therapy is
ithdrawn or never initiated. These results persisted even
fter controlling for differences between the patient groups.
n addition, continuation of beta-blocker therapy was very
ell tolerated, with 93.6% of those continued and dis-
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Beta-Blocker Continuation or Withdrawal in HF July 15, 2008:190–9harged on beta-blocker therapy remaining on treatment
uring follow-up. The HF patients withdrawn from beta-
lockers during hospitalization were substantially less likely
o be treated with beta-blockers after discharge, which likely
ontributed to these patients’ poor outcomes. These findings
uggest that routine discontinuation of beta-blocker therapy on
ospital admission is neither necessary nor advisable, and the
ajority of patients hospitalized for HF are eligible for beta-
locker therapy to be continued. The present study provides
eal-world support of recent guideline recommendations that,
henever possible, beta-blocker therapy should be continued
n patients hospitalized with HF.
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APPENDIX
or a list of variables included in multivariable
nalysis, please see the online version of this article.
